The Coffee That Pays You Back!

Fine out more information about Ganoderma in our Coffee's and Tea's at www.americashealthiercoffee.com
Showing posts with label Glucose. Show all posts
Showing posts with label Glucose. Show all posts

Friday, January 4, 2013

Brown Adipose Tissue Beneficial For Metabolism And Glucose Tolerance

Main Category: Diabetes
Also Included In: Obesity / Weight Loss / Fitness
Article Date: 12 Dec 2012 - 1:00 PST Current ratings for:
Brown Adipose Tissue Beneficial For Metabolism And Glucose Tolerance
not yet ratednot yet rated
Joslin Diabetes Center scientists have demonstrated that brown adipose tissue (BAT) has beneficial effects on glucose tolerance, body weight and metabolism. The findings, which may lead to new treatments for diabetes, appear in the upcoming issue of the Journal of Clinical Investigation.

Unlike the more prevalent white adipose tissue (WAT or white fat) which stores fat, BAT (or brown fat) burns fat to produce heat. Studies in mice and humans have suggested that BAT also plays a role in regulating body weight and metabolism. This has made BAT the focus of considerable interest among scientists and pharmaceutical companies who are investigating ways to use BAT as a treatment for obesity.

The Joslin researchers were interested in learning whether BAT is involved in glucose metabolism and uncovering the mechanisms underlying BAT's effects on metabolism and body weight. The study involved the transplantation of BAT from male donor mice into the visceral cavities of mice which were fed a standard or high-fat diet.

By eight to twelve weeks following transplantation, the BAT-transplanted mice fed a normal diet showed improved glucose tolerance, increased insulin sensitivity, lower body weights and decreased fat mass. Three control groups, which had a WAT transplant, a glass bead implant or surgery without transplantation, did not show any metabolic improvements. "We were able to establish that BAT transplantation affects metabolism. This study provides further evidence that BAT is a very important metabolic organ and a potential treatment for obesity-related diseases such as diabetes, metabolic syndrome and insulin resistance," says lead author Kristin I. Stanford, PhD, a postdoctoral fellow in the Section on Integrative Physiology and Metabolism.

The mice fed a high-fat diet also exhibited beneficial effects from BAT transplantation, including improved glucose metabolism, decreased body weight and a complete reversal of insulin resistance resulting from excess fat consumption. Previous studies of BAT transplantation in mice, which transplanted BAT in a different location and had a shorter duration, did not show beneficial effects.

The transplanted BAT affected metabolism throughout the body by increasing levels of circulating Interleukin-6 (IL-6). The researchers also found that BAT transplantation increased norepinephrine and FGF-21. IL-6 has been shown in previous studies to increase energy production and decrease body weight. When the researchers transplanted BAT from donor mice genetically engineered not to produce IL-6, the mice who received the transplants showed no metabolic improvements. "This is the first study to demonstrate that an increase in BAT significantly increases levels of circulating IL-6. It suggests that an increase in BAT-derived IL-6 improves glucose metabolism throughout the body," says senior author Laurie J. Goodyear, PhD, head of the Section on Integrative Physiology and Metabolism.

The researchers are following up on the study by "looking into other ways BAT may have beneficial metabolic effects and further investigating the functions of IL-6 and other BAT-derived hormones," says Dr. Goodyear. Dr. Stanford is studying the relationship between BAT and type 1 diabetes (T1D), based on data from a collaborator that suggests that BAT may help control glucose in T1D.

Dr. Goodyear and the research team are very interested in using their findings to develop new therapies for diabetes. "We hope that manipulating BAT will help people with type 1 and type 2 diabetes," says Dr. Goodyear.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our diabetes section for the latest news on this subject.
Study co-authors include: Roeland J. W. Middelbeek, Kristy L. Townsend, Ding An, Eva B. Nygaard, Kristen M. Hitchcox, Kathleen R. Markan, Kazuhiro Nakano, Michael F. Hirshman, Yu-Hua Tseng, all of Joslin Diabetes Center.

The study was funded by the National Institutes of Health.

Joslin Diabetes Center

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Brown Adipose Tissue Beneficial For Metabolism And Glucose Tolerance." Medical News Today. MediLexicon, Intl., 12 Dec. 2012. Web.
31 Dec. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Brown Adipose Tissue Beneficial For Metabolism And Glucose Tolerance'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Thursday, January 3, 2013

Blood Glucose Levels And BMI In Very Obese Children Improved By Metformin

Main Category: Obesity / Weight Loss / Fitness
Also Included In: Diabetes;  Pediatrics / Children's Health
Article Date: 13 Dec 2012 - 0:00 PST Current ratings for:
Blood Glucose Levels And BMI In Very Obese Children Improved By Metformin
not yet ratednot yet rated
Metformin therapy has a beneficial treatment effect over placebo in improving body mass index (BMI) and fasting glucose levels in obese children, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). The study showed reduction in BMI was sustained for six months.

Childhood obesity has increased globally over the last two decades and it is linked to an increase in the diagnosis of type 2 diabetes in childhood, previously a condition that was only diagnosed in adults. Metformin is a first line drug for type 2 diabetes, and has been used for many decades. In adults metformin delays the onset of type 2 diabetes, but there is no evidence that the drug has a similar effect on children.

"Our findings provide evidence that a treatment course of metformin is clinically useful, safe and well-tolerated in obese children who are at risk for type 2 diabetes," said Deborah Kendall, MD, of Royal Manchester Children's Hospital in the United Kingdom and lead author of the study. "Metformin may also provide stimulus for lifestyle changes and potentially reduce long-term risk for type 2 diabetes and its associated health problems."

This prospective, randomized, double-blind, placebo-controlled trial was conducted at six pediatric endocrine centers in the United Kingdom and involved 151 obese children and young people with hyperinsulinemia and/or impaired fasting glucose or impaired glucose tolerance. Study participants received either metformin or placebo daily for six months. This trial is the largest of its kind to focus on metformin in obese non-diabetic children and young people.

"Our results show that metformin can improve BMI and blood glucose levels in obese children, but longer term effects such as reduction in the incidence of type 2 diabetes need further study," noted Kendall.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our obesity / weight loss / fitness section for the latest news on this subject.
Other researchers working on the study include: R. Amin, F. Ivison, A. McGovern, L. Tetlow, P. Clayton and C. Hall of Royal Manchester Children's Hospital; T. Barrett of Birmingham Children's Hospital, UK; P. Dimitri, J. Wales and N. Wright of the University of Sheffield, UK; M. Kibirige of The James Cook University Hospital, UK; V. Mathew of Hull Royal Infirmary, UK; K. Matyka and H. Stirling of University Hospital Coventry and Warwickshire National Health Service Trust, UK; and A. Vail of the Centre of Biostatistics, UK.

The article, "Metformin in Obese Children and Adolescents: The MOCA Trial," appears in the January 2013 issue of JCEM.

The Endocrine Society

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Blood Glucose Levels And BMI In Very Obese Children Improved By Metformin." Medical News Today. MediLexicon, Intl., 13 Dec. 2012. Web.
31 Dec. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Blood Glucose Levels And BMI In Very Obese Children Improved By Metformin'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, July 10, 2012

Kidney Failure In Type 2 Diabetes May Not Be Reduced By Aggressive Glucose Control

Main Category: Diabetes
Also Included In: Urology / Nephrology
Article Date: 29 May 2012 - 1:00 PDT Current ratings for:
'Kidney Failure In Type 2 Diabetes May Not Be Reduced By Aggressive Glucose Control'
3 stars4 stars
Yale School of Medicine researchers have found that intensively controlling glucose (glycemic) levels in type-2 diabetes patients may not reduce the risk of kidney failure. The study, which is a review of data from seven clinical trials, is published in the May 28 issue of Archives of Internal Medicine.

To test the hypothesis that aggressive glycemic control can prevent renal disease in patients with type 2 diabetes mellitus, first author Steven G. Coca of Yale and colleagues searched available medical literature and evaluated seven randomized trials involving 28,065 adult patients who were monitored for two to 15 years.

The team found that compared with those who had usual treatment, intensively controlling glucose with higher doses of medication did not definitively reduce the risk of impaired kidney function, the need for dialysis, or death from kidney disease.

Coca said many researchers have presumed that such intensive treatment would benefit patients by protecting the kidneys, but these results question whether patients truly are better off with this approach.

"After pooling the results from the follow-up data in the seven studies examined, our analysis shows that intensive glycemic control may improve some things about the kidney that we measure, but did not affect patients' outcomes," said Coca, assistant professor in the section of nephrology in the Department of Internal Medicine at Yale.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our diabetes section for the latest news on this subject. Other authors on the study include Faramarz Ismail-Beigi, Nowreen Haq, Harlan M. Krumholz, and Chirag R. Parikh.
The study was funded in part by the National Heart, Lung, and Blood Institute Center for Cardiovascular Outcomes Research at Yale University. Krumholz is also the recipient of a research grant from Medtronic, Inc. through Yale University.
Citation: Arch Intern Med. Vol. 172, No. 10 (May 28, 2012)
Yale University Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Yale University. "Kidney Failure In Type 2 Diabetes May Not Be Reduced By Aggressive Glucose Control." Medical News Today. MediLexicon, Intl., 29 May. 2012. Web.
7 Jun. 2012. APA

Please note: If no author information is provided, the source is cited instead.



'Kidney Failure In Type 2 Diabetes May Not Be Reduced By Aggressive Glucose Control'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here